Reclassification guide

Reclassification guide

Learn about medicines reclassified from prescription-only (POM) or general sale to pharmacy medicines (P), with guidance to support safe supply.

Published: 13 March 2025

This was published when the organisation was the Royal Pharmaceutical Society.


More medicines are being reclassified from prescription-only medicines (POMs) to pharmacy (P) medicines. 

Other medicines, such as oral lidocaine-containing products for teething in children, have been reclassified from general sale list medicines to P medicines. 

We’ve produced guidance to support you when selling or supplying these medicines.

Read more RCPharm pharmacy guides.

How to navigate medicines reclassifications 

Watch our webinar with the Medicines and Healthcare products Regulatory Agency (30 March 2021)

Further information

The following medicines have also been considered by the government for reclassification:

  • Dovonex Psoriasis Ointment – The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Dovonex Psoriasis Ointment 50mg from a POM to a P medicine in the UK.
  • Otrivine extra dual-relief nasal spray – MHRA has agreed to reclassify Otrivine extra dual-relief nasal spray from POM to a P medicine in the UK.

One-to-one support

Monday-Friday, 9am to 5pm
We’ll answer your questions, provide reliable professional advice, and point you towards the most up-to-date pharmaceutical information.

Did this learning help your CPD?

Don’t forget to record it in your MyCPD Revalidation
e-Portfolio.

Share your suggestions

Submit an idea for learning content, events, guidance or resources.